Novartis’ Capmatinib (INC280) Receives FDA’s Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer

 Novartis’ Capmatinib (INC280) Receives FDA’s Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer

Novartis’ Capmatinib (INC280) Receives FDA’s Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer

Shots:

  • The US FDA has accepted NDA and granted PR designation to Capmatinib as a 1L treatment for LA/m- MET exon 14 skipping (METex14) mutated NSCLC
  • The NDA submission is based on GEOMETRY mono-1 P-II study that demonstrated ORR (67.9%) assessed by BIRC assessment per RECIST v1.1, mDOR (11.4 and 9.72 mos.) in treatment naïve and prior treated patients respectively
  • Capmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor with its expected review to be completed within 6mos. The therapy is licensed from Incyte in 2009, under which Novartis got WW exclusive development and commercialization rights for the therapy and certain back-up compounds in all indications

Click here to­ read full press release/ article | Ref: Novartis | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post